sur Lonza Group AG (isin : CH0013841017)
Lonza Reveals Restated Financials for Half-Year 2025
Lonza Group AG has published its restated financial figures for the first half of 2025. This adjustment mirrors the earlier decision to classify its Capsules & Health Ingredients (CHI) division as discontinued operations, conforming with the full-year 2025 reports.
In December 2024, Lonza announced its plan to divest the CHI business. On 6 March 2026, the company confirmed an agreement to sell CHI to Lone Star Funds, with completion anticipated in the third quarter of 2026. The revised financials incorporate an updated income statement and key performance metrics, yet they do not alter the previously reported overall results for 2025.
The restated data is available for review online. Lonza continues to operate as a leading global contract development and manufacturing organization in the healthcare sector.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Lonza Group AG